Table 3.

Published studies of RFA and high-dose SBRT group of the present study

Study, year	Treatment	Study type	Number	Tumor size (cm)	Local control (%)	Overall survival (%)	Severe toxicity (%)
Shiina 2005 (7)	RFA	RCT	118	Median 2.2	98	74 (4-year)	5.1
Bouza 2009 (8)	RFA	Meta-analysis	396	Mean 2.6	93	62 (4-year)	4.1
Waki 2010 (38)	RFA	Retrospective	88	Median 1.8	95	70 (5-year)	5.7
Feng 2012 (39)	RFA	RCT	84	Mean 2.4	96	67 (3-year)	9.5
Shiina 2012 (6)	RFA	Retrospective	1170	Median 2.0 Mean 2.5	97	60 (5-year)	2.2
Present study(> 54 Gy)	SBRT	Retrospective	32 (Rec 53%)	Median 3.0 Mean 3.1	100	68 (4.5-year)	Bowel 3.1; Others 3.1

Abbreviations: SBRT stereotactic body radiotherapy, RFA radiofrequency ablation, RCT randomized controlled trial, Rec, recurrence.

Comparison between recent data concerning published RFA for hepatocellular carcinoma and high-dose (> 54 Gy) SBRT group of the present study. In these RFA series, all patients had initial disease and received RFA as the first treatment.